Profile data is unavailable for this security.
About the company
Solasia Pharma KK is a Japan-based company with a product development pipeline of pharmaceuticals and medical devices, and is engaged in the development and sale of pharmaceuticals. Its main business area is the development and sale of pharmaceuticals for the treatment of malignant tumors. It also develops and sells pharmaceuticals and medical devices that are expected to reduce adverse events caused by the administration of malignant tumor treatment drugs and radiation therapy, and improve the treatment of malignant tumors and the quality of life (QOL) of patients. It is engaged in in-licensing of rights for pharmaceutical or medical device candidate substances, development of pharmaceutical candidates, and monetization of pharmaceutical candidates. Its development pipeline includes the transdermal granisetron preparation Sancuso, the organic arsenic preparation darinaparsin, the oral wound dressing protective material episil, and the intracellular superoxide remover PledOx.
- Revenue in JPY (TTM)408.00m
- Net income in JPY-1.18bn
- Incorporated2007
- Employees24.00
- LocationSolasia Pharma KK3F, Shiodome Bldg., 1-2-20, KaiganMINATO-KU 105-0011JapanJPN
- Phone+81 358438045
- Fax+81 367212020
- Websitehttps://solasia.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perseus Proteomics Inc | 100.40m | -1.10bn | 4.12bn | 24.00 | -- | 2.65 | -- | 41.00 | -93.74 | -93.74 | 8.52 | 117.15 | 0.0471 | 3.35 | 8.55 | -- | -51.85 | -41.34 | -54.94 | -43.43 | 87.33 | 91.72 | -1,100.04 | -891.26 | 12.77 | -- | -- | -- | 6.58 | -18.31 | -40.34 | -- | 60.30 | -- |
| Delta-Fly Pharma Inc | 0.00 | -1.43bn | 4.34bn | 11.00 | -- | 3.52 | -- | -- | -197.24 | -197.24 | 0.00 | 149.78 | 0.00 | -- | -- | -- | -120.07 | -67.70 | -141.25 | -72.02 | -- | -- | -- | -- | -- | -243.15 | -- | -- | -- | -- | -7.57 | -- | -9.04 | -- |
| BrightPath Biotherapeutics Co Ltd | 72.00k | -1.17bn | 4.40bn | 32.00 | -- | 4.48 | -- | 61,088.34 | -18.30 | -18.30 | 0.0011 | 13.84 | 0.00005 | -- | 2.36 | -- | -79.69 | -51.56 | -87.69 | -54.32 | 75.00 | 68.63 | -1,622,336.00 | -22,321.82 | -- | -435.39 | 0.1031 | -- | -98.64 | -78.47 | 21.37 | -- | -46.55 | -- |
| Renascience Inc | 194.17m | -258.34m | 4.61bn | 3.00 | -- | 2.87 | -- | 23.77 | -20.32 | -20.32 | 15.27 | 126.40 | 0.089 | -- | -- | -- | -11.84 | -- | -12.49 | -- | 85.31 | -- | -133.05 | -- | -- | -- | 0.1814 | -- | 93.11 | -- | 23.07 | -- | -- | -- |
| Immuno-Biological Laboratories Co., Ltd. | 816.70m | 186.69m | 4.69bn | 60.00 | 25.14 | 3.71 | -- | 5.75 | 20.05 | 20.05 | 87.69 | 135.86 | 0.535 | 0.9358 | 4.53 | -- | 12.23 | -13.97 | 14.68 | -16.39 | 63.34 | 57.73 | 22.86 | -39.23 | 3.65 | -- | 0.1572 | -- | 2.78 | 0.8924 | 164.44 | -- | -- | -- |
| OncoTherapy Science, Inc. | 610.12m | -1.29bn | 4.79bn | 60.00 | -- | 12.31 | -- | 7.85 | -6.09 | -6.09 | 2.87 | 1.62 | 0.513 | 9.08 | 7.69 | -- | -108.31 | -55.67 | -182.73 | -63.82 | -29.13 | -1.49 | -211.13 | -247.47 | 2.07 | -189.93 | 0.232 | -- | -46.24 | 16.81 | -15.15 | -- | -48.33 | -- |
| Kringle Pharma Inc | 77.93m | -904.81m | 4.93bn | 13.00 | -- | 2.03 | -- | 63.27 | -159.92 | -159.92 | 13.58 | 356.64 | 0.027 | -- | 2.80 | 5,994,308.00 | -31.29 | -19.00 | -33.20 | -20.23 | -- | -- | -1,161.12 | -156.51 | 12.85 | -- | 0.00 | -- | -82.33 | -- | -157.41 | -- | -- | -- |
| Kidswell Bio Corp | 2.43bn | -1.42bn | 5.08bn | 41.00 | -- | 6.04 | -- | 2.09 | -40.81 | -40.81 | 68.79 | 21.35 | 0.5415 | 1.84 | 2.47 | -- | -31.67 | -57.41 | -51.25 | -81.13 | 42.75 | 55.20 | -58.49 | -123.52 | 1.70 | -28.91 | 0.7559 | -- | -12.43 | 18.93 | -116.31 | -- | -- | -- |
| KAINOS Laboratories, Inc. | 5.06bn | 637.97m | 5.26bn | 144.00 | 7.57 | 0.7757 | 6.95 | 1.04 | 152.41 | 152.41 | 1,206.78 | 1,486.43 | 0.6053 | 3.08 | 4.55 | -- | 7.64 | 6.92 | 9.96 | 9.26 | 50.46 | 51.84 | 12.62 | 10.80 | 2.43 | -- | 0.1221 | 18.46 | 2.71 | 1.60 | 12.28 | 10.57 | -9.83 | 16.36 |
| Solasia Pharma KK | 408.00m | -1.18bn | 5.53bn | 24.00 | -- | 2.80 | -- | 13.56 | -6.96 | -6.96 | 2.40 | 10.01 | 0.1432 | 2.01 | 3.06 | 17,000,000.00 | -41.50 | -48.57 | -53.67 | -58.83 | 51.23 | 71.01 | -289.71 | -300.89 | 1.68 | -400.00 | 0.2327 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| Cyfuse Biomedical KK | 64.79m | -645.40m | 5.98bn | 21.00 | -- | 1.95 | -- | 92.37 | -82.27 | -82.27 | 8.26 | 378.39 | 0.0153 | 0.5202 | 13.80 | 3,085,095.00 | -15.19 | -- | -17.68 | -- | 61.81 | -- | -996.19 | -- | 6.39 | -81.61 | 0.2126 | -- | -83.68 | -- | -24.32 | -- | -- | -- |
| DNA Chip Research Inc | 490.46m | -248.29m | 6.09bn | 36.00 | -- | 8.31 | -- | 12.42 | -39.09 | -39.09 | 77.17 | 108.27 | 0.5292 | 9.84 | 3.11 | -- | -26.79 | -23.49 | -32.60 | -26.70 | 13.53 | 14.28 | -50.62 | -54.10 | 2.92 | -2,206.97 | -- | -- | 49.74 | 6.33 | 31.48 | -- | -15.75 | -- |
| Noile-Immune Biotech Inc | 311.30m | -975.80m | 6.28bn | 28.00 | -- | 1.17 | -- | 20.17 | -22.56 | -22.56 | 7.19 | 123.55 | 0.0658 | 0.139 | 5.07 | 11,118,000.00 | -20.62 | -- | -21.29 | -- | 99.55 | -- | -313.45 | -- | 52.74 | -805.65 | 0.00 | -- | -49.37 | -- | -192.28 | -- | -- | -- |
| MEDRx Co Ltd | 22.57m | -770.66m | 6.55bn | 22.00 | -- | 3.11 | -- | 290.10 | -20.97 | -20.97 | 0.6128 | 47.84 | 0.0143 | 0.00 | 4.22 | 1,025,955.00 | -48.80 | -58.15 | -50.27 | -62.23 | 100.00 | 95.70 | -3,414.38 | -1,526.17 | 43.57 | -- | 0.00 | -- | -50.35 | 28.60 | 16.04 | -- | -55.29 | -- |
| NIPPON CHEMIPHAR CO., LTD. | 30.75bn | -180.00m | 6.67bn | 872.00 | -- | 0.3059 | 5.70 | 0.2169 | -49.89 | -49.89 | 8,520.20 | 5,115.78 | 0.6268 | 2.14 | 2.70 | -- | -0.3689 | 0.7482 | -0.5204 | 1.08 | 25.17 | 30.99 | -0.5887 | 1.13 | 1.53 | -- | 0.4791 | 50.33 | -2.57 | -2.10 | -153.10 | -- | 24.62 | -12.94 |
| Chiome Bioscience Inc | 642.70m | -1.30bn | 6.88bn | 51.00 | -- | 5.45 | -- | 10.70 | -25.56 | -25.56 | 12.60 | 22.39 | 0.3348 | 4.27 | 8.96 | 12,602,040.00 | -67.53 | -50.50 | -88.83 | -57.38 | 55.96 | 57.53 | -201.70 | -224.74 | 3.46 | -629.88 | 0.2009 | -- | 8.19 | 26.24 | 1.84 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to Solasia Pharma KK's reporting currency: Japanese Yen JPY
1.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rheos Capital Works, Inc. (Investment Management)as of 30 Sep 2022 | 2.32m | 1.20% |
| Simplex Asset Management Co., Ltd.as of 09 May 2024 | 718.30k | 0.37% |
Data from 31 Mar 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.
